People In Brief: Pfizer, Valeant, Vitalah, Aker, Mulberry Love
This article was originally published in The Tan Sheet
Schulman out, Bourla in at Pfizer; Valeant appoints Kellen chairman; Vitalah VP leads Oxylent sales; Aker names Australia head; CRN builds regulatory team; more People In Brief.
You may also be interested in...
Consumer health products are grouped with vaccines and oncology drugs in Pfizer’s internal reorganization that takes effect in January 2014. Pfizer’s realignment into three organizations represents a step in the firm’s multi-year deliberation over whether to split its business.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.